摘要
目的探讨齐拉西酮与利培酮对急性期精神分裂症患者临床疗效及对QT间期的影响。方法回顾性分析120例急性期精神分裂症患者,将齐拉西酮治疗的60例患者设定为观察组,利培酮治疗的60例患者设置为对照组,比较2组患者的临床疗效及心电图QT间期。结果观察组总有效率、治疗前2组患者阴性因子、阳性因子评分与对照组相比,差异无统计学意义(P>0.05)。治疗后4周末、8周末观察组阴性因子评分、阳性因子评分显著优于对照组(P<0.01)。治疗前2组患者QT、QTc间期差异无统计学意义(P>0.05)。治疗后4周末、8周末观察组QT间期、QTc间期显著优于对照组(P<0.01)。观察组患者治疗前与治疗后8周末相比QT、QTc间期无延长(P>0.05),对照组患者则显著延长(P<0.01)。观察组不良反应的发生显著低于对照组(P<0.05)。结论急性期精神分裂症患者采用齐拉西酮与利培酮的临床效果相当,在采用利培酮治疗的过程中应当特别注意心电监测。
Objective To investigate the clinical efficacy of Ziprasidone and Risperidone in patients with acute schizophrenia and their effects on QT interval.Methods The clinical data of 120 patients with acute schizophrenia were retrospectively analyzed.Sixty patients treated with Ziprasidone were included as the study group,and sixty patients treated with Risperidone were included as the control group.The clinical efficacy and electrocardiogram QT interval in the two groups were compared.Results There were no statistically significant differences in the total effective rate and the scores of negative factors and positive factors at baseline between the study group and control group(all P>0.05).At 4 and 8 weeks after the treatment,the scores of negative factors and positive factors in the study group were better than those in the control group(all P<0.01).There were no statistically significant differences in QT and QTc intervals at baseline between the two groups(both P>0.05).At 4 and 8 weeks after the treatment,theQT and QTc intervals in the study group were better than those in the control group(all P<0.01).The QT and QTc intervals in the study group were not prolonged at baseline compared with those at 8 weeks after the treatment(P>0.05),while those in the control group were significantly prolonged(P<0.01).The incidence of adverse reactions in the study group was significantly lower than that in the control group(P<0.05).Conclusion The clinical effects of Ziprasidone and Risperidone in patients with acute schizophrenia are equivalent.Special attention should be paid to ECG monitoring during the treatment of Risperidone.
作者
冒海瀛
杨建军
Mao Haiying;Yang Jianjun(Department of Psychiatry,Mental Health Center of Baoshan District,Shanghai 201900,China)
出处
《中国药物与临床》
CAS
2021年第16期2776-2778,共3页
Chinese Remedies & Clinics
